174 related articles for article (PubMed ID: 27659012)
1. Induction of Activating Transcription Factor 3 Is Associated with Cisplatin Responsiveness in Non-Small Cell Lung Carcinoma Cells.
Bar J; Hasim MS; Baghai T; Niknejad N; Perkins TJ; Stewart DJ; Sekhon HS; Villeneuve PJ; Dimitroulakos J
Neoplasia; 2016 Sep; 18(9):525-35. PubMed ID: 27659012
[TBL] [Abstract][Full Text] [Related]
2. Lovastatin-induced apoptosis is mediated by activating transcription factor 3 and enhanced in combination with salubrinal.
Niknejad N; Gorn-Hondermann I; Ma L; Zahr S; Johnson-Obeseki S; Corsten M; Dimitroulakos J
Int J Cancer; 2014 Jan; 134(2):268-79. PubMed ID: 23824972
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of cisplatin cytotoxicity by disulfiram involves activating transcription factor 3.
O'Brien A; Barber JE; Reid S; Niknejad N; Dimitroulakos J
Anticancer Res; 2012 Jul; 32(7):2679-88. PubMed ID: 22753726
[TBL] [Abstract][Full Text] [Related]
4. Induction of ferroptosis by ATF3 elevation alleviates cisplatin resistance in gastric cancer by restraining Nrf2/Keap1/xCT signaling.
Fu D; Wang C; Yu L; Yu R
Cell Mol Biol Lett; 2021 Jun; 26(1):26. PubMed ID: 34098867
[TBL] [Abstract][Full Text] [Related]
5. MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer.
Cortes-Sempere M; Chattopadhyay S; Rovira A; Rodriguez-Fanjul V; Belda-Iniesta C; Tapia M; Cejas P; Machado-Pinilla R; Manguan-García C; Sánchez-Pérez I; Nistal M; Moratilla C; de Castro-Carpeño J; Gonzalez-Barón M; Albanell J; Perona R
Cancer Lett; 2009 Dec; 286(2):206-16. PubMed ID: 19553005
[TBL] [Abstract][Full Text] [Related]
6. miR Profiling Identifies Cyclin-Dependent Kinase 6 Downregulation as a Potential Mechanism of Acquired Cisplatin Resistance in Non-Small-Cell Lung Carcinoma.
Bar J; Gorn-Hondermann I; Moretto P; Perkins TJ; Niknejad N; Stewart DJ; Goss GD; Dimitroulakos J
Clin Lung Cancer; 2015 Nov; 16(6):e121-9. PubMed ID: 25703099
[TBL] [Abstract][Full Text] [Related]
7. Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization.
Fischer C; Leithner K; Wohlkoenig C; Quehenberger F; Bertsch A; Olschewski A; Olschewski H; Hrzenjak A
Mol Cancer; 2015 Jan; 14():4. PubMed ID: 25608569
[TBL] [Abstract][Full Text] [Related]
8. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
Ibanez de Caceres I; Cortes-Sempere M; Moratilla C; Machado-Pinilla R; Rodriguez-Fanjul V; Manguán-García C; Cejas P; López-Ríos F; Paz-Ares L; de CastroCarpeño J; Nistal M; Belda-Iniesta C; Perona R
Oncogene; 2010 Mar; 29(11):1681-90. PubMed ID: 20023704
[TBL] [Abstract][Full Text] [Related]
9. TR4 nuclear receptor enhances the cisplatin chemo-sensitivity via altering the ATF3 expression to better suppress HCC cell growth.
Shen J; Lin H; Li G; Jin RA; Shi L; Chen M; Chang C; Cai X
Oncotarget; 2016 May; 7(22):32088-99. PubMed ID: 27050071
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin induces cytotoxicity through the mitogen-activated protein kinase pathways and activating transcription factor 3.
St Germain C; Niknejad N; Ma L; Garbuio K; Hai T; Dimitroulakos J
Neoplasia; 2010 Jul; 12(7):527-38. PubMed ID: 20651982
[TBL] [Abstract][Full Text] [Related]
11. NDRG1 Downregulates ATF3 and Inhibits Cisplatin-Induced Cytotoxicity in Lung Cancer A549 Cells.
Du A; Jiang Y; Fan C
Int J Med Sci; 2018; 15(13):1502-1507. PubMed ID: 30443171
[TBL] [Abstract][Full Text] [Related]
12. KiSS-1 Modulation by Epigenetic Agents Improves the Cisplatin Sensitivity of Lung Cancer Cells.
Beretta GL; Alampi D; Corno C; Carenini N; Corna E; Perego P
Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732265
[TBL] [Abstract][Full Text] [Related]
13. Chaetocin induces endoplasmic reticulum stress response and leads to death receptor 5-dependent apoptosis in human non-small cell lung cancer cells.
Liu X; Guo S; Liu X; Su L
Apoptosis; 2015 Nov; 20(11):1499-507. PubMed ID: 26349783
[TBL] [Abstract][Full Text] [Related]
14. IL-6 signaling contributes to cisplatin resistance in non-small cell lung cancer via the up-regulation of anti-apoptotic and DNA repair associated molecules.
Duan S; Tsai Y; Keng P; Chen Y; Lee SO; Chen Y
Oncotarget; 2015 Sep; 6(29):27651-60. PubMed ID: 26313152
[TBL] [Abstract][Full Text] [Related]
15. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
[TBL] [Abstract][Full Text] [Related]
16. ATF3 and Fra1 have opposite functions in JNK- and ERK-dependent DNA damage responses.
Hamdi M; Popeijus HE; Carlotti F; Janssen JM; van der Burgt C; Cornelissen-Steijger P; van de Water B; Hoeben RC; Matsuo K; van Dam H
DNA Repair (Amst); 2008 Mar; 7(3):487-96. PubMed ID: 18249159
[TBL] [Abstract][Full Text] [Related]
17. MKP1 mediates chemosensitizer effects of E1a in response to cisplatin in non-small cell lung carcinoma cells.
Cimas FJ; Callejas-Valera JL; Pascual-Serra R; García-Cano J; Garcia-Gil E; De la Cruz-Morcillo MA; Ortega-Muelas M; Serrano-Oviedo L; Gutkind JS; Sánchez-Prieto R
Oncotarget; 2015 Dec; 6(42):44095-107. PubMed ID: 26689986
[TBL] [Abstract][Full Text] [Related]
18. Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT.
Tièche CC; Peng RW; Dorn P; Froment L; Schmid RA; Marti TM
BMC Cancer; 2016 Feb; 16():125. PubMed ID: 26895954
[TBL] [Abstract][Full Text] [Related]
19. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer.
Chattopadhyay S; Machado-Pinilla R; Manguan-García C; Belda-Iniesta C; Moratilla C; Cejas P; Fresno-Vara JA; de Castro-Carpeño J; Casado E; Nistal M; Gonzalez-Barón M; Perona R
Oncogene; 2006 Jun; 25(23):3335-45. PubMed ID: 16462770
[TBL] [Abstract][Full Text] [Related]
20. Targeting the invasive phenotype of cisplatin-resistant non-small cell lung cancer cells by a novel histone deacetylase inhibitor.
Zuco V; Cassinelli G; Cossa G; Gatti L; Favini E; Tortoreto M; Cominetti D; Scanziani E; Castiglioni V; Cincinelli R; Giannini G; Zunino F; Zaffaroni N; Lanzi C; Perego P
Biochem Pharmacol; 2015 Mar; 94(2):79-90. PubMed ID: 25600908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
